作为一家新兴的医疗器械公司,Inari Medical, Inc.(NARI)近期股价大涨12.08%,引发市场广泛关注。推动这一涨势的主因是公司2024年第三季度业绩数据优于预期。
Inari Medical第三季度财报显示,公司调整后每股亏损仅为9美分,远好于分析师预期的11美分亏损水平。营收方面,公司实现营收1.5339亿美元,较去年同期增长21.4%,也超出了市场预期。
虽然Inari Medical目前仍处于亏损状态,但近年来其业绩一直保持着高速增长态势。该公司的良好表现加上医疗器械行业广阔的发展前景,使其长期成长潜力获得分析师的一致看好。多家机构上调了对该公司的目标价,认为其长期成长空间广阔。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.